20 Participants Needed

Stem Cell Selection for Blood Diseases

MS
LH
Overseen ByLauren Harrison, RN
Age: < 65
Sex: Any
Trial Phase: Phase 2
Sponsor: Mitchell Cairo
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Prior Safety DataThis treatment has passed at least one previous human trial
Approved in 2 JurisdictionsThis treatment is already approved in other countries

Trial Summary

What is the purpose of this trial?

Children, adolescents, and young adults with malignant and non-malignant conditionsundergoing an allogeneic stem cell transplantation (AlloSCT) will have the stem cells selected utilizing α/β CD3+/CD19+ cell depletion. All other treatment is standard of care.

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

What data supports the effectiveness of the treatment Alpha/Beta Depletion, Alpha/Beta T Cell Depletion, TCR αβ+ T Cell Depletion, α/β CD3+ T-cell and CD19+ B-cell depletion for blood diseases?

Research shows that TCR-alpha/beta and CD19 depletion is effective in engineering grafts for children with acute myeloid leukemia (AML), achieving a 100% primary engraftment rate and a 67% overall survival rate at 2 years. This suggests that the treatment can be a robust method for managing high-risk blood diseases.12345

Is stem cell treatment with TCR-alpha/beta and CD19 depletion safe for humans?

Research shows that TCR-alpha/beta and CD19 depletion in stem cell treatments is generally safe, with low rates of severe complications like graft-versus-host disease (a condition where the donor cells attack the recipient's body) and non-relapse mortality (death not related to the return of the disease).12567

How is the Alpha/Beta Depletion treatment unique for blood diseases?

The Alpha/Beta Depletion treatment is unique because it selectively removes specific immune cells (TCR alpha/beta+ T cells and CD19+ B cells) from donor stem cell grafts, which can help reduce complications like graft-versus-host disease (a condition where donor cells attack the recipient's body) while preserving beneficial cells like natural killer cells. This approach is particularly useful in stem cell transplants from partially matched donors, offering a more targeted and potentially safer alternative to traditional methods.12358

Research Team

MS

Mitchell S Cairo

Principal Investigator

New York Medical College

Eligibility Criteria

This trial is for children and young adults (0-30 years) with various blood diseases, including high-risk acute leukemia, lymphoma, sickle cell disease, and bone marrow failure syndromes. Participants must have adequate organ function and not be pregnant or breastfeeding. They can't join if they've had a recent transplant or uncontrolled infection.

Inclusion Criteria

I have Sickle Cell Disease.
I have been diagnosed with high-risk Myelodysplastic syndrome.
I have a bone marrow failure syndrome and treatments haven't worked for me.
See 5 more

Exclusion Criteria

I do not have any untreated infections.
I am not pregnant or breastfeeding.
I had a stem cell transplant from a donor less than 6 months ago, not as a boost.
See 3 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Conditioning

Patients receive full intensity, reduced intensity, or reduced toxicity conditioning based on disease and other factors

2-3 weeks

Transplantation

Patients undergo α/β T-cell and CD 19+ B cell depleted allogeneic stem cell transplantation

1 week

Post-transplant Monitoring

Patients are monitored for engraftment, chimerism, immune reconstitution, GVHD, and QOL

1 year

Follow-up

Participants are monitored for safety and effectiveness after treatment

1 year

Treatment Details

Interventions

  • Alpha/Beta Depletion
Trial OverviewThe study tests a stem cell transplantation technique using α/β CD3+/CD19+ cell depletion in patients with malignant and non-malignant hematologic conditions. This method aims to improve outcomes by selecting specific cells while maintaining standard care treatments.
Participant Groups
1Treatment groups
Experimental Treatment
Group I: alpha beta cell depletionExperimental Treatment1 Intervention
Matched allogeneic donor stem cells will be processed utilizing α/β CD3+/CD19+ cell depletion with the Prodigy system. Standard pre-conditioning and post-transplant motioning will be given.

Alpha/Beta Depletion is already approved in United States, European Union for the following indications:

🇺🇸
Approved in United States as CliniMACS CD34 Reagent System for:
  • Acute Myeloid Leukemia (AML) in first complete remission undergoing allogeneic HCT from a matched related donor
🇪🇺
Approved in European Union as CliniMACS System for:
  • Hematopoietic reconstitution following a myeloablative preparative regimen without the need for additional GVHD prophylaxis in patients with AML in first morphologic complete remission (CR1)

Find a Clinic Near You

Who Is Running the Clinical Trial?

Mitchell Cairo

Lead Sponsor

Trials
2
Recruited
60+

Findings from Research

In a study of 273 patients receiving T cell-depleted marrow using the T10B9 antibody, higher doses of TCR gamma delta + T cells were significantly associated with better engraftment probabilities, suggesting their beneficial role in the transplantation process.
TCR alpha beta + T cells were linked to a higher risk of acute graft-versus-host disease (GVHD) in recipients of related donor marrow, while TCR gamma delta + T cells did not increase this risk, indicating that different T cell subsets have distinct impacts on engraftment and GVHD outcomes.
Effect of T cell subset dose on outcome of T cell-depleted bone marrow transplantation.Kawanishi, Y., Passweg, J., Drobyski, WR., et al.[2006]
Aggressive T-cell depletion is crucial for the success of haplo-identical stem cell transplantation, but traditional methods have resulted in high transplant-related mortality, with only a 20% overall survival rate.
The study found that while the recovery of CD34+ and NK cells was generally high, the T- and B-cell depletion process was not consistently effective, leading to the consideration of alternative protocols for better outcomes.
CD3/CD19 Depletion for T-cell Reduction of Allogeneic Transplants: Mostly Efficient, but not Robust.Wiercinska, E., Seifried, E., Bonig, H.[2021]
Plerixafor significantly improved the collection of CD34+ hematopoietic progenitor cells in pediatric allogeneic donors, achieving a median increase of 14.8-fold in poor mobilizers and 6.5-fold in insufficient mobilizers, compared to a 3.45-fold increase with G-CSF alone.
The use of plerixafor was safe, with only mild to moderate side effects reported, and it did not compromise the purity of TCR-alpha/beta depletion in the apheresis product.
Plerixafor added to G-CSF allows mobilization of a sufficient number of hematopoietic progenitors without impacting the efficacy of TCR-alpha/beta depletion in pediatric haploidentical and genoidentical donors failing to mobilize with G-CSF alone.Kurnikova, E., Trakhtman, P., Pershin, D., et al.[2022]

References

Effect of T cell subset dose on outcome of T cell-depleted bone marrow transplantation. [2006]
CD3/CD19 Depletion for T-cell Reduction of Allogeneic Transplants: Mostly Efficient, but not Robust. [2021]
Plerixafor added to G-CSF allows mobilization of a sufficient number of hematopoietic progenitors without impacting the efficacy of TCR-alpha/beta depletion in pediatric haploidentical and genoidentical donors failing to mobilize with G-CSF alone. [2022]
Combining the Disease Risk Index and Hematopoietic Cell Transplant Co-Morbidity Index provides a comprehensive prognostic model for CD34+-selected allogeneic transplantation. [2022]
TCR-alpha/beta and CD19 depletion and treosulfan-based conditioning regimen in unrelated and haploidentical transplantation in children with acute myeloid leukemia. [2022]
TCRαβ/CD19 cell-depleted HLA-haploidentical transplantation to treat pediatric acute leukemia: updated final analysis. [2023]
[An effective method for T-cell and B-cell simultaneous depletion in vitro from mobilized peripheral blood stem/progenitor cell graft for haploidentical transplantation]. [2017]
Depletion of αβ+ T and B Cells Using the CliniMACS Prodigy: Results of 10 Graft-Processing Procedures from Haploidentical Donors. [2022]